Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: "prodromal" Clear all
Completed No phase listed Observational Accepts healthy volunteers

TRC-PAD Program: In-Clinic Trial-Ready Cohort

NCT04004767
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 9, 2026, 8:54 AM EDT
Active, not recruiting No phase listed Observational

The Syn-Sleep Study

NCT05757206
View directory record Official record
Conditions
REM Sleep Behavior Disorder (iRBD)
Interventions
Syn-One Test
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

NCT03520036
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
MT-7117 low dose, MT-7117 high dose, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Recruiting Phase 2 Interventional

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

NCT05519111
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Completed No phase listed Observational

Imaging Biomarkers in Parkinson s Disease

NCT01496599
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Not listed No phase listed Observational

Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD

NCT04406636
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years to 63 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
San Diego, California • Englewood, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

NCT01224106
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 9, 2026, 8:54 AM EDT
Terminated No phase listed Observational Results available

Natural History Study in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

NCT05020743
View directory record Official record
Conditions
ALSP
Interventions
No intervention
Other
Lead sponsor
Vigil Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
San Francisco, California • Englewood, Colorado • Boca Raton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226
View directory record Official record
Conditions
Schizophrenia Prodrome
Interventions
Glycine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders

NCT03388294
View directory record Official record
Conditions
Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions
Parents and Infants Engaged
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Months to 16 Months
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Feasibility Trial of a Lifestyle Intervention for CHR-P

NCT05532683
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
Interventions
Health Behaviors Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

NCT04402489
View directory record Official record
Conditions
EPP, XLP
Interventions
Placebo, MT-7117 Low Dose, MT-7117 High Dose
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Huntington Beach, California • Miami, Florida • Brighton, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

NCT03303456
View directory record Official record
Conditions
Psychosis, Clinical High Risk for Psychosis
Interventions
Mobile health application - Ginger.io
Other
Lead sponsor
University of California, Davis
Other
Eligibility
13 Years to 30 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 9, 2026, 8:54 AM EDT
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 9, 2026, 8:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neuroplasticity in RBD

NCT05471960
View directory record Official record
Conditions
REM Sleep Behavior Disorder
Interventions
Natural progression over time
Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 9, 2026, 8:54 AM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCT03230097
View directory record Official record
Conditions
Psychotic Disorders
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
16 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Culver City, California • San Diego, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 9, 2026, 8:54 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 9, 2026, 8:54 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores

NCT01902303
View directory record Official record
Conditions
Oral Herpes Simplex
Interventions
Matching Placebo, BTL-TML-HSV
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
St. Petersburg, Florida • Cincinnati, Ohio • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

NCT04029623
View directory record Official record
Conditions
Prodromal Alzheimer's Disease
Interventions
Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK)
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
View directory record Official record
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Suspended Phase 1Phase 2 Interventional

Accelerated TMS in Psychosis

NCT05567848
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Prodromal Schizophrenia
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 9, 2026, 8:54 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone in the Psychosis Prodrome

NCT00635700
View directory record Official record
Conditions
Psychosis Prodrome
Interventions
ziprasidone, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years to 40 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 9, 2026, 8:54 AM EDT